2018. IFX postop

RCT/Infliximab/CD/ Postop recurrence

Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan

Randomized multicenter open trial. Patients with CD having surgery with ileocolonic anastomosis or colo-colonic anastomosis were randomized to IFX 5mg/kg (0,2,6

and q8w) or control arm.

5ASA or elemental diet postsurgery were possible.

Primary endpoints: Endoscopic or clinical recurrence in 2 years.

<u>Results:</u>

- Disease recurrence rate IFX 52.6% vs 94.7% in the control group, p<0.05

Conclusion:

The postoperative use of IFX is effective in preventing Crohn's disease recurrence for 2 years.




Fig. 2 The recurrence rate after 2 years. The disease recurrence rate in the infliximab group was significantly lower than that in the noninfliximab group

þ